Trehan Shubam, Singh Gurjot, Bector Gaurav, Jain Prateek, Mehta Tejal, Goswami Kanishka, Chawla Avantika, Jain Aayush, Puri Piyush, Garg Nadish
Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, IND.
Internal Medicine, Maharaj Sawan Singh Charitable Hospital, Beas, IND.
Cureus. 2024 Aug 16;16(8):e67010. doi: 10.7759/cureus.67010. eCollection 2024 Aug.
Cardiovascular diseases (CVDs) are a leading cause of mortality worldwide. Recent research has identified gut dysbiosis - an imbalance in the gut microbiota - as a significant factor in the development of CVDs. This complex relationship between gut microbiota and cardiovascular health involves various mechanisms, including the production of metabolites such as trimethylamine N-oxide (TMAO) and short-chain fatty acids (SCFAs). These metabolites influence lipid metabolism, inflammation, and blood pressure regulation. In addition, the gut-brain axis and neurohormonal pathways play crucial roles in cardiovascular function. Epidemiological studies have linked gut dysbiosis to various cardiovascular conditions, highlighting the potential for therapeutic interventions. Dietary changes, probiotics, and prebiotics have shown promise in modulating gut microbiota and reducing cardiovascular risk factors. This underscores the critical role of gut health in preventing and treating CVDs. However, further research is needed to develop targeted therapies that can enhance cardiovascular outcomes.
心血管疾病(CVDs)是全球主要的死亡原因。最近的研究已确定肠道菌群失调——肠道微生物群失衡——是心血管疾病发展的一个重要因素。肠道微生物群与心血管健康之间的这种复杂关系涉及多种机制,包括三甲胺N-氧化物(TMAO)和短链脂肪酸(SCFAs)等代谢物的产生。这些代谢物会影响脂质代谢、炎症和血压调节。此外,肠脑轴和神经激素途径在心血管功能中起关键作用。流行病学研究已将肠道菌群失调与各种心血管疾病联系起来,凸显了治疗干预的潜力。饮食改变、益生菌和益生元已显示出调节肠道微生物群和降低心血管危险因素的前景。这强调了肠道健康在预防和治疗心血管疾病中的关键作用。然而,需要进一步研究以开发能够改善心血管结局的靶向治疗方法。